Spots Global Cancer Trial Database for hyperparathyroidism, secondary
Every month we try and update this database with for hyperparathyroidism, secondary cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid | NCT02274623 | Breast Cancer Prostate Cancer Bone Neoplasms Hypocalcemia Hyperparathyroi... | CTAP101 Capsule... | 18 Years - | OPKO Health, Inc. | |
| Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass | NCT02830789 | Roux-en-Y Gastr... Hyperparathyroi... | Calcium Carbona... Calcium Citrate Placebo Roux-en-Y gastr... | 20 Years - 70 Years | University of Aarhus | |
| Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis | NCT01181531 | Hyperparathyroi... | Traditional Vit... Cinacalcet | 18 Years - | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis | NCT01785849 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy | NCT05382988 | Sodium Zirconiu... Hyperkalemia Hyperparathyroi... | Sodium zirconiu... | - | Guangdong Provincial People's Hospital | |
| A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis | NCT01922843 | Hyperparathyroi... Kidney Failure,... | DP001 softgel c... Placebo | 18 Years - | Deltanoid Pharmaceuticals | |
| Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 | NCT02282813 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 Capsule... Calcitriol Doxercalciferol Paricalcitol | 18 Years - | OPKO Health, Inc. | |
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) | NCT01219855 | Chronic Kidney ... Secondary Hyper... Vitamin D Insuf... | Cohort 1 CTAP10... Cohort 1 CTAP10... Cohort 1 Matchi... Cohort 2 CTAP10... Cohort 2 Matchi... | 18 Years - 85 Years | OPKO Health, Inc. | |
| Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency | NCT01704079 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 30 μg c... Sugar pill to C... | 18 Years - | OPKO Health, Inc. | |
| Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 | NCT02282813 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 Capsule... Calcitriol Doxercalciferol Paricalcitol | 18 Years - | OPKO Health, Inc. | |
| Treatment of Secondary Hyperparathyroidism in the Uremic Patient | NCT00469599 | Secondary Hyper... Chronic Kidney ... Vitamin D Defic... | paricalcitol alfacalcidol | 18 Years - | Zealand University Hospital | |
| Optimal Anemia Treatment in End Stage Renal Disease (ERSD) | NCT02273570 | Hyperparathyroi... | standard care Optimal (I. iPT... | 18 Years - | Azienda Ospedaliera Sant'Anna | |
| Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency | NCT01651000 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 30 μg c... Sugar pill to C... | 18 Years - | OPKO Health, Inc. | |
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide | NCT01932970 | Hyperparathyroi... | Etelcalcetide | 18 Years - 100 Years | Amgen | |
| Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01785875 | Hyperparathyroi... | Etelcalcetide | 18 Years - 100 Years | Amgen | |
| Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism | NCT01439867 | Chronic Kidney ... Hyperparathyroi... | Cinacalcet hydr... Standard of Car... | 28 Days - 2189 Days | Amgen | |
| Treatment of Secondary Hyperparathyroidism in the Uremic Patient | NCT00469599 | Secondary Hyper... Chronic Kidney ... Vitamin D Defic... | paricalcitol alfacalcidol | 18 Years - | Zealand University Hospital | |
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) | NCT01219855 | Chronic Kidney ... Secondary Hyper... Vitamin D Insuf... | Cohort 1 CTAP10... Cohort 1 CTAP10... Cohort 1 Matchi... Cohort 2 CTAP10... Cohort 2 Matchi... | 18 Years - 85 Years | OPKO Health, Inc. | |
| Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) | NCT00792857 | Chronic Kidney ... Secondary Hyper... Chronic Renal I... Chronic Renal F... | CTAP201 Injecti... Doxercalciferol | 18 Years - 80 Years | OPKO Health, Inc. | |
| Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide | NCT01932970 | Hyperparathyroi... | Etelcalcetide | 18 Years - 100 Years | Amgen | |
| A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis | NCT01922843 | Hyperparathyroi... Kidney Failure,... | DP001 softgel c... Placebo | 18 Years - | Deltanoid Pharmaceuticals | |
| Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism | NCT01439867 | Chronic Kidney ... Hyperparathyroi... | Cinacalcet hydr... Standard of Car... | 28 Days - 2189 Days | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01788046 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | NCT01290029 | Chronic Kidney ... Hyperparathyroi... Secondary Hyper... | Cinacalcet | 28 Days - 2190 Days | Amgen | |
| Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01788046 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| Pediatric Chronic Kidney Disease Safety and Efficacy | NCT01277510 | Chronic Kidney ... Hyperparathyroi... Hyperparathyroi... Kidney Disease Secondary Hyper... | cinacalcet caps... placebo Standard of Car... | 6 Years - 17 Years | Amgen | |
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01788046 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | NCT01290029 | Chronic Kidney ... Hyperparathyroi... Secondary Hyper... | Cinacalcet | 28 Days - 2190 Days | Amgen | |
| Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass | NCT02830789 | Roux-en-Y Gastr... Hyperparathyroi... | Calcium Carbona... Calcium Citrate Placebo Roux-en-Y gastr... | 20 Years - 70 Years | University of Aarhus | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis | NCT01785849 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
